Ixovex-1

AXP000057.1 · Oncolytic virus

Platform
adenovirus (Ad5, E1B splice-variant mutant)
Originator
Psivac
Sponsor
Psivac

Names

NameTypeSource
Ixovex-1preferred name, codecurator, ctgov

Virus

Role
Oncolytic
Family
Adenoviridae
Virus
human adenovirus 5 (NCBI Taxonomy 28285)
Strain
Ad5 (Ixovex-1)
Replication
conditionally replicating
Modifications
E1B splice-variant mutant
Route
intratumoral
Source
evidence

Approvals

No regulatory approval recorded.

Clinical trials (1)

TrialTitleStatusPhaseStartPrimary completionEnrolmentConditions
NCT06549946Ixovex-1 Single Agent and Combination TherapyRecruitingPhase 1/22024-12-172027-01-3018Head and Neck Cancer; Solid Tumor

Recent changes

No changes recorded in its trials yet.

Clinical papers

No confirmed clinical papers yet.

Other papers

Preclinical studies, reviews and other papers that name it.

PubMedTitleJournalYearLinked by
PMID 35596069Ixovex-1, a novel oncolytic E1B-mutated adenovirus.Cancer gene therapy2022name in title: Ixovex-1

Notes

Phase 1/2 NCT06549946, alone and with pembrolizumab. Described by the developer as an E1B-mutant oncolytic adenovirus; exact mutation not confirmed from a primary source.

How to cite

Ixovex-1 (AXP000057.1). The Abstractinator program registry, release 2026-11-17+2c46e992acfc. https://abstractinator.me/registry/AXP000057.html

Something wrong or missing? Suggest a correction (a GitHub issue; please link your evidence). Entry created 2026-11-11, updated 2026-11-11.